Skip to content Skip to footer
Subscribe Now
CXO Talks: Tim O’Connell from Emtelligent in a Striking Conversation with PharmaShots
SPOTLIGHT

CXO Talks: Tim O’Connell from Emtelligent in a Striking Conversation with PharmaShots

Shots: In this episode of the CXO Talks podcast, PharmaShots spoke with Tim O’Connell, CEO of Emtelligent, a next-generation medical AI company Tim highlights Emtelligent’s inspiring journey to becoming a leader in a clinical-grade NLP company focused on transforming unstructured data to actionable insights at an enterprise scale Emtelligent leverages the power of medical records…
June 9, 2025

Read more

Spotlight Interview_UWE Tigor_JED Litwinuik
SPOTLIGHT

CXO Talks: Jed Litwiniuk & Uwe Tigör from Auxilius Pharma in a Riveting Dialogue Exchange with PharmaShots

In this fifth episode of our recently launched CXO Talks, we spoke with a distinguished panel of speakers from Auxilius Pharma, Jed Litwiniuk, the CEO, and Uwe Tigör, the CMO of the company. Auxilius Pharma is an emerging specialized pharma company aimed at developing, optimizing, and delivering well-established medications internationally.  Jed & Uwe walked memory…
November 11, 2024

Read more

VIEWPOINTS_Jason Hannon_2024
VIEWPOINTS

Funds Raised: Jason Hannon from Mainstay Medical in a Stimulating Conversation with PharmaShots

Shots: Mainstay Medical recently raised $125M in the company’s largest funding round. The financing is intended to accelerate the commercial growth of the company’s ReActiv8, a restorative Neurostimulation therapy in the US, Europe, and Australia Today, at PharmaShots, we had Jason Hannon, CEO of Mainstay Medical, who talked in great length about the ReActiv8 Restorative Neuromodulation System developed for…
May 27, 2024

Read more

VIEWPOINTS_Raviv Pryluk_2024
VIEWPOINTS

Technology Infusion: Raviv Pryluk Sheds Light on PhaseV’s Recent Collaboration with 9xchange Biopharma Marketplace

Shots:  Raviv Pryluk, CEO and Co-Founder of PhaseV, in a stimulating conversation with PharmaShots, sheds light on the company’s recent partnership with 9xchange Biopharma   The partnership aims to bring Phase V’s proprietary machine learning (ML) technology to ecosystem members, enabling them, to retrospectively analyze and optimally design and execute advanced clinical studies  Raviv highlights the…
April 23, 2024

Read more

VIEWPOINTS_Mo Jain_2024
VIEWPOINTS

Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services

Shots: Following the roll-out of high throughput discovery proteomics services, Mo Jain, Founder and CEO of Sapient engages in a stimulating conversation with PharmaShots Unlike conventional mass spectrometry-based proteomics methodologies in the market, Sapient’s Discovery Proteomics Services leverage the nanoparticle enrichment technology to measure more proteins and PTMs within the plasma proteome While highlighting Sapient’s…
April 16, 2024

Read more

Spotlight Interview_David A. Dodd
SPOTLIGHT

Spotlight Interview: David A. Dodd, CEO at GeoVax Labs, in an Engaging Conversation with PharmaShots

PharmaShots’ Spotlight offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people. This week at the Spotlight, we had a riveting discussion with David A. Dodd, Chairman, President & CEO, at GeoVax Labs. David eloquently highlighted GeoVax’s extraordinary journey over the years from…
February 26, 2024

Read more

Spotlight Interview_David Esposito
SPOTLIGHT

Spotlight Interview: David Esposito CEO at ONL Therapeutics in a Stimulating Conversation with PharmaShots

“Spotlight-Company of the Month” offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people. This month at PharmaShots’ Spotlight, we had an opportunity to engage in conversation with David Esposito CEO at ONL Therapeutics. David discusses the company's lead candidate ONL1204, which is…
February 19, 2024

Read more

VIEWPOINTS_David Domzalski_2024
VIEWPOINTS

Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement

Shots: David Domzalski, President & Chief Executive Officer at VYNE Therapeutics, in an invigorating conversation with PharmaShots The PIPE transaction generated $88M ensuring a steady cash flow through the end of 2025 and multiple anticipated clinical catalysts across VYNE’s BET inhibitor platform David believes the financing will be instrumental in the advancement of VYN201, into…
January 29, 2024

Read more

Load more